Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
作者： M. Debiec-Rychter , H. Dumez , I. Judson , B. Wasag , J. Verweij
DOI: 10.1016/J.EJCA.2003.11.025
关键词:
摘要: … Two tumours with no detectable c-KIT mutations demonstrated PDGFRA Asp→Glu 842 amino acid substitutions. Patients with GISTs harbouring exon 11 mutations were more likely to …
core.ac.uk
kuleuven.be
elsevier.com
sci-hub.se 参考文章(16)
Lisa Sarran, Peter Besmer, Ronald P DeMatteo, Sylvia J Tschernyavsky, Marc Ladanyi, Robert Maki, Mark Robson, Elyn Riedel, James M Woodruff, Murray F Brennan, Cristina R Antonescu, Gunhild Sommer, Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research. ,vol. 9, pp. 3329- 3337 ,(2003)
Jerzy Lasota, Agnieszka Wozniak, Maarit Sarlomo-Rikala, Janusz Rys, Radzislaw Kordek, Aziza Nassar, Leslie H. Sobin, Markku Miettinen, Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. American Journal of Pathology. ,vol. 157, pp. 1091- 1095 ,(2000) , 10.1016/S0002-9440(10)64623-8
Allan T van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, Andrew Webb, Raf Sciot, Martine Van Glabbeke, Sandra Silberman, Ole S Nielsen, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. ,vol. 358, pp. 1421- 1423 ,(2001) , 10.1016/S0140-6736(01)06535-7
Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461
Eva Wardelmann, Iris Neidt, Erhard Bierhoff, Nicola Speidel, Christoph Manegold, Hans-Peter Fischer, Ulrich Pfeifer, Torsten Pietsch, c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant Modern Pathology. ,vol. 15, pp. 125- 136 ,(2002) , 10.1038/MODPATHOL.3880504
Michael C Heinrich, Charles D Blanke, Brian J Druker, Christopher L Corless, Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies Journal of Clinical Oncology. ,vol. 20, pp. 1692- 1703 ,(2002) , 10.1200/JCO.20.6.1692
Hui Chen, Koji Isozaki, Kazuo Kinoshita, Akiko Ohashi, Yasuhisa Shinomura, Yuji Matsuzawa, Yukihiko Kitamura, Seiichi Hirota, Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors International Journal of Cancer. ,vol. 105, pp. 130- 135 ,(2003) , 10.1002/IJC.11025
David A Tuveson, Nicholas A Willis, Tyler Jacks, James D Griffin, Samuel Singer, Christopher DM Fletcher, Jonathan A Fletcher, George D Demetri, STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications Oncogene. ,vol. 20, pp. 5054- 5058 ,(2001) , 10.1038/SJ.ONC.1204704
David A. Tuveson, George D. Demetri, Anette Duensing, Sheng Xiao, Brian P. Rubin, Christopher D. M. Fletcher, Connie Tsao, Marcia L. Lux, Michele K. Hibbard, Samuel Singer, Jonathan A. Fletcher, Robert Ruiz, Chang-Jie Chen, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research. ,vol. 61, pp. 8118- 8121 ,(2001)
J Verweij, A van Oosterom, J.-Y Blay, I Judson, S Rodenhuis, W van der Graaf, J Radford, A Le Cesne, P.C.W Hogendoorn, E.D di Paola, M Brown, O.S Nielsen, Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. European Journal of Cancer. ,vol. 39, pp. 2006- 2011 ,(2003) , 10.1016/S0959-8049(02)00836-5